ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 289

HDL Modified with Malondialdehyde-Acetaldehyde (MAA) Is Bound and Rapidly Internalized By Human THP-1 Monocytes

Michael J. Duryee1, Dahn L Clemens2, Logan M. Duryee2, Karen C. Easterling3, Carlos D. Hunter4, Lynell W. Klassen5, James R. O'Dell6, Daniel R. Anderson2, Ted R. Mikuls5 and Geoffrey M. Thiele2, 1Research Services, Omaha VA Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 5Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 6Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Macrophage and inflammation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Innate Immunity and Rheumatic Disease Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased cardiovascular disease (CVD) burden, one that appears to be mitigated by increased concentrations of circulating HDL resulting from effective disease-modifying treatment. Our group has demonstrated that proteins modified with malondialdehyde-acetaldehyde (MAA), are present in the synovial tissues of RA patients and atherosclerotic lesions from non-RA patients with CVD. Previous data has also shown that MAA-modified proteins are bound and internalized by scavenger receptors (SRs) (SRA, SRBI, LOX-1, and CD36) present on immune cells. Therefore, in this study we evaluated whether HDL is modified by MAA and bound or internalized by monocytes. 

Methods: Human HDL was labeled with 1,1′-dioctadecyl-3,3,3’3′-tetramethylindocarbocyanine perchlorate (DIL-HDL).  For MAA modification DIL-HDL (1 mg/ml) was incubated with 2mM malondialdehyde and 1mM acetaldehyde for 3 days and fluorescence of the dihydropyridine structure determined. To evaluate receptor mediated binding and internalization, PMA activated THP-1 cells (human monocytic) were incubated on ice at either 4oC or 37oC (respectively) for 90 minutes with 25 μg/ml of DIL-Albumin, DIL-HDL and DIL-HDL-MAA.  Cells were washed, fixed in paraformaldehyde, and subjected to flow cytometry at 594 nm wavelength. Analysis was performed using FlowJo V10.  Data are expressed as percent positive compared to the DIL-labeled human albumin.    

Results: Human HDL was modified at 30,000 fluorescent units (FU), which was greater than the MAA modification observed for human serum albumin (22,000 FU).   As shown in the Figure, THP-1 cells bound HDL (41.73%) at the cell surface significantly better than HDL-MAA (17.55%; P<0.001).  Internalization studies revealed that HDL-MAA (48.9%) was taken up more by the cells than HDL (39.14%) alone, although this difference did not achieve statistical significance. 

Conclusion: These data show that HDL can be modified with the MAA adduct and HDL-MAA is subsequently bound and internalized by human monocytes.  THP-1 cells contain multiple scavenger receptors capable of binding and internalizing altered self-ligands as a normal clearance mechanism.  These results demonstrate that HDL modified with MAA is bound at lower levels that HDL alone, but is internalized more efficiently by human monocytes  Taken together, these results suggest that MAA modification could impact cellular trafficking of HDL, thus influencing CVD pathogenesis in conditions characterized by oxidative stress and increased MAA adduct formation.


Disclosure: M. J. Duryee, None; D. L. Clemens, None; L. M. Duryee, None; K. C. Easterling, None; C. D. Hunter, None; L. W. Klassen, None; J. R. O'Dell, Medac, 5,Coherus, 5; D. R. Anderson, None; T. R. Mikuls, BMS, 2,Ironwood Pharm, 2,Pfizer Inc, 5,NIH, VA, 2; G. M. Thiele, None.

To cite this abstract in AMA style:

Duryee MJ, Clemens DL, Duryee LM, Easterling KC, Hunter CD, Klassen LW, O'Dell JR, Anderson DR, Mikuls TR, Thiele GM. HDL Modified with Malondialdehyde-Acetaldehyde (MAA) Is Bound and Rapidly Internalized By Human THP-1 Monocytes [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/hdl-modified-with-malondialdehyde-acetaldehyde-maa-is-bound-and-rapidly-internalized-by-human-thp-1-monocytes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hdl-modified-with-malondialdehyde-acetaldehyde-maa-is-bound-and-rapidly-internalized-by-human-thp-1-monocytes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology